Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02555449 · ClinicalTrials.gov registry record · Phase 1
A Study of [¹⁴C]-LY3202626 in Healthy Male Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02555449 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 6 participants.
The verdict
NCT02555449, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to measure how much of the specially prepared study drug, LY3202626, containing radiolabeled carbon \[¹⁴C\] gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected. Participants will stay at a clinical research unit (CRU). The study will last about 28 days (check in to follow-up) for each participant. This study is for research purposes only and is not intended to treat any medical condition.
Interventions
- DRUG [¹⁴C]-LY3202626
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-09 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02555449
The ClinicalTrials.gov registry entry for NCT02555449 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [¹⁴C]-LY3202626 is the first listed.
NCT02555449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02555449 about?
NCT02555449 is a clinical study titled "A Study of [¹⁴C]-LY3202626 in Healthy Male Participants". The purpose of this study is to measure how much of the specially prepared study drug, LY3202626, containing radiolabeled carbon \[¹⁴C\] gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected. Participant...
What is the current status of trial NCT02555449?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2015-09. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02555449?
The interventions under investigation include: [¹⁴C]-LY3202626 (DRUG).
Who is sponsoring clinical trial NCT02555449?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.